IGM Biosciences stock has experienced a significant decline, indicating an overall bearish sentiment in the market. The company's high expenses and poor financial management have devalued the company.

Higher interest rates and worries about banking system stability and a recession have rocked the market and caused the energy and financial Sectors to sell off. Surprisingly enough to some investors, ...

The iShares Expanded Tech Sector ETF (NYSEARCA:IGM) is a comprehensive ETF that gives investors exposure to the full spectrum of the North American tech sector, as it includes key tech-related stocks ...

BMO Capital raised the firm’s price target on IGM Financial (IGIFF) to C$57 from C$54 and keeps a Market Perform rating on the shares. Published ...

4 analysts have expressed a variety of opinions on IGM Biosciences (NASDAQ:IGMS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

IGM Biosciences, Inc. is halting the development of its bispecific antibodies imvotamab and IGM-2644 due to insufficient data from clinical trials, specifically regarding B cell depletion for treating ...

Thinking about whether to buy, hold, or part ways with IGM Financial? You are not alone. This stock has prompted plenty of second looks, especially after its robust run. Just over the past week, ...

IGM Financial Inc. reported third-quarter net earnings of $298.1 million, up 24.6% from the same quarter of last year, the ...

In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:IGMS), offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...